Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2019-01-24, Stock:LLY, The news for the past five days is as follows:
2019-01-16: NEWS1: 5 Health Care Stocks in Gurus' Portfolios.NEWS2: Kitov Pharma's Stock Up on Anti-Cancer Candidate Findings.NEWS3: Intrexon Signs Licensing Agreement with Next Green Wave.NEWS4: Ligand Crashes To Nearly 2-Year Low After Short-Seller Bashes It.NEWS5: Goldman's Gold Standard in M&A Bolsters Outlook for 2019.NEWS6: Takeda Wraps Its Shire Buyout, CEO Sees More Mergers Coming.NEWS7: 6 Reasons Why You Should Buy Eli Lilly (LLY) Stock in 2019.NEWS8: 6 Reasons Why You Should Buy Eli Lilly (LLY) Stock in 2019.NEWS9: 6 Reasons Why You Should Buy Eli Lilly (LLY) Stock in 2019.
2019-01-17: NEWS1: FDA Turns Down IMMU's Breast Cancer Drug, MGNX/LLY Deal Progresses, ZFGN Abuzz.NEWS2: FDA Turns Down IMMU's Breast Cancer Drug, MGNX/LLY Deal Progresses, ZFGN Abuzz.NEWS3: Lilly&apos;s 10-Day Sprint For Loxo Could Put Other Names On The Table.NEWS4: Lilly's 10-Day Sprint For Loxo Could Put Other Names On The Table.NEWS5: Ligand (LGND) Takes a Hit on Citron's Negative Research Report.NEWS6: Citron Says Ligand Has 80% Downside in Explosive Note.NEWS7: Dealmaking surge confirms the stock market got far too ch....NEWS8: Jim Cramer: There's a Ton More Deals in the Pipe.
2019-01-18: NEWS1: Health Care Sector Update for 01/18/2019: CRON,LLY,EW,LXRX.NEWS2: Health Care Sector Update for 01/18/2019: CRON,LLY,EW,LXRX.NEWS3: Eli Lilly Slides as Sarcoma Treatment Fails in Phase 3 Trial.NEWS4: Highly Rated Pharma Dips On Drug Failure — Is Its Buy Point At Risk?.NEWS5: Eli Lilly News: LLY Stock Falls on Sarcoma Study Failure.NEWS6: Lilly cancer drug fails key trial, will no longer be prescribed.NEWS7: Health Care Sector Update for 01/18/2019: LLY,EW,LXRX.NEWS8: Health Care Sector Update for 01/18/2019: LLY,EW,LXRX.NEWS9: [$$] Lilly's Sarcoma Drug Combo Proves Ineffective in Trials.NEWS10: Health care, retail, biotech & emerging markets in the bl....NEWS11: Stocks making the biggest moves midday: Netflix, Boeing, Tesla, Eli Lilly & more.NEWS12: Stocks making the biggest moves midday: Netflix, Boeing, Tesla, Eli Lilly & more.NEWS13: Pharma Stock Roundup: Regulatory Updates in Focus at PFE, BMY, RHHBY, SNY.NEWS14: Pharma Stock Roundup: Regulatory Updates in Focus at PFE, BMY, RHHBY, SNY.NEWS15: S&P 500 Movers: NFLX, VFC.NEWS16: S&P 500 Movers: NFLX, VFC.NEWS17: Lilly's cancer therapy Lartruvo fails study, shares drop.NEWS18: Here is Why Growth Investors Should Buy Lilly (LLY) Now.NEWS19: Here is Why Growth Investors Should Buy Lilly (LLY) Now.NEWS20: FDA Turns Down IMMU's Breast Cancer Drug, ZYME/LLY Deal Progresses, ZFGN Abuzz.NEWS21: FDA Turns Down IMMU's Breast Cancer Drug, ZYME/LLY Deal Progresses, ZFGN Abuzz.NEWS22: Health Care Sector Update for 01/18/2019: LXRX, SNY, SNSS, LLY, JNJ, PFE, MRK, ABT, AMGN.NEWS23: Health Care Sector Update for 01/18/2019: LXRX, SNY, SNSS, LLY, JNJ, PFE, MRK, ABT, AMGN.NEWS24: Dow jumps 160 points as stock market set to end week with solid gains on China-trade optimism.NEWS25: Pharma Stock Roundup: Regulatory Updates in Focus at PFE, BMY, RHHBY, SNY.NEWS26: Here is Why Growth Investors Should Buy Lilly (LLY) Now.NEWS27: Pacira's Study on Exparel Label Expansion Meets Endpoints.NEWS28: Pacira's Study on Exparel Label Expansion Meets Endpoints.NEWS29: Ligand (LGND) Takes a Hit on Citron's Negative Research Report.NEWS30: Ligand (LGND) Takes a Hit on Citron's Negative Research Report.NEWS31: Stocks making the biggest moves premarket: Tesla, CVS Health, Eli Lilly, Netflix & more.NEWS32: Lilly's cancer therapy Lartruvo fails to meet main goal in late-stage trial.NEWS33: Eli Lilly shares slide premarket on news of failed trial for sarcoma treatment.NEWS34: Lilly Reports Results of Phase 3 Soft Tissue Sarcoma Study of LARTRUVO®.NEWS35: Lilly : Phase 3 Soft Tissue Sarcoma Study Fails Not Meet Primary Endpoints.NEWS36: Lilly : Phase 3 Soft Tissue Sarcoma Study Fails Not Meet Primary Endpoints.NEWS37: Pacira's Study on Exparel Label Expansion Meets Endpoints.
2019-01-22: NEWS1: U.S. insulin costs per patient nearly doubled from 2012 to 2016 -study.NEWS2: J&J's (JNJ) Q4 Earnings Beat, 2019 Sales Forecast Soft.NEWS3: J&J's (JNJ) Q4 Earnings Beat, 2019 Sales Forecast Soft.NEWS4: Company News For Jan 22, 2019.NEWS5: J&J's (JNJ) Q4 Earnings Beat, 2019 Sales Forecast Soft.NEWS6: Company News For Jan 22, 2019.NEWS7: See what the IHS Markit Score report has to say about Eli Lilly and Co..NEWS8: U.S. insulin costs per patient nearly doubled from 2012 to 2016 -study.
2019-01-23: NEWS1: Noteworthy ETF Outflows: XLV, ABT, LLY, TMO.NEWS2: Noteworthy ETF Outflows: XLV, ABT, LLY, TMO.NEWS3: 5 Best Biotech Bets Likely to Outperform Estimates in Q4.NEWS4: How Many Insiders Bought Eli Lilly and Company (NYSE:LLY) Shares?.NEWS5: 3 Upcoming Readouts for Gilead Sciences You Don't Want to Miss.NEWS6: 3 Upcoming Readouts for Gilead Sciences You Don't Want to Miss.NEWS7: 6 Stocks to Prepare for a Global Economic Slowdown.NEWS8: Government Employees Affected by Federal Shutdown Encouraged to Contact Lilly Diabetes Solution Center to Access Insulin.

Answer: Decrease